白血病抑制因子受体在婴幼儿血管瘤组织中的表达及意义

目的:探讨白血病抑制因子受体(LIFR)在婴幼儿血管瘤增殖、消退中的作用。方法:应用SP免疫组织化学方法检测LIFR与CD133、Ki67在血管瘤52例(按Takahashi等的标准分类,其中增生期A组30例,消退期B组22例)、血管畸形16例、正常包皮皮肤15例中的表达水平。所有资料应用软件包进行统计分析,P<0.05具有统计学意义。结果:增殖期血管瘤组LIFR、CD133、Ki67表达水平分别高于消退期血管瘤组、血管畸形组及正常皮肤组,差异具有统计学意义(P<0.01);消退期血管瘤组LIFR、CD133、Ki67阳性细胞率与血管畸形及正常皮肤组织相比,差异无统计学意义(P>0.05)。LIFR与CD133、Ki67在血管瘤组织中表达的阳性率有统计学意义(P<0.01)。结论:①LIFR的表达与血管瘤的增殖与退化过程有着密切关系;②CD133表达阳性的细胞参与了血管瘤的发生与发展过程;③LIFR与CD133、Ki67三者在小儿血管瘤的发生、发展过程中可能具有相互调节和协同的作用。

The expression and role of LIFR in infantile hemangiomas

Objective: To investigate the role of LIFR in proliferation and involution of infantile hemangiomas.Methods: 52 samples of infantile hemangiomas(30 samples in proliferating phase,22 samples in involution phase classified according criterion of Takahashi),16 samples of vascular malformation and 15 samples of normal skin were obtained from patients underwent surgery from 2009 to 2010.The expressions of LIFR CD133 and Ki67 were examined with SP method of immunohistochemieal technique.The data were dealt with soft SPSS17.0,and less than 0.05 was considered significant.Results: In proliferating phase,a number of vascular endothelial cells highly expressed LIFR、CD133 and Ki67.It was significantly higher than in involution phase,vascular malformation,and normal skin.The difference between proliferating hemangioma and involuting hemangioma was significant(P<0.05).But no significant difference between involuting hemangioma,vascular malformation and normal skin(P>0.05).By spearman’s rank correlation,there were positive correlation relationships among the expressions of LIFR、CD133 and Ki67 in infantile hemangiomas.Conclusions:①Overexpression of LIFR in proliferating hemangioma may correlate with the development of hemangioma.②The cell with high expression of CD133 may play a very important role in the proliferation of infantile hemangiomas.③The expression of LIFR has a positive correlation with CD133 and Ki67 in hemangioma.It may be concluded that LIFR can intensify the expression of CD133 and Ki67 in proliferating hemangioma.